Various studies indicated that the restoration of CFTR function by correctors and/or potentiators in leukocytes promotes the normalization of inflammation and infection in CF patients, suggesting the potential of leukocyte outcomes as useful parameters to be examined in clinical trials utilizing CFTR modulators [19,35]. The gene discussed is CFTR; the disease is cystic fibrosis.